Savara (SVRA) News Today $2.91 +0.13 (+4.68%) Closing price 04:00 PM EasternExtended Trading$2.94 +0.03 (+1.20%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Analysts Conflicted on These Healthcare Names: Savara (SVRA) and Zentalis Pharmaceuticals (ZNTL)March 28 at 7:13 PM | markets.businessinsider.comSavara reports Q4 EPS (13c), consensus (11c)March 27 at 6:52 PM | markets.businessinsider.comSavara completes BLA submission to FDA for MolbreeviMarch 27 at 8:50 AM | markets.businessinsider.comSavara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business UpdateMarch 27 at 7:05 AM | businesswire.comSavara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules CapitalMarch 26 at 4:45 PM | businesswire.comSavara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)March 26 at 4:05 PM | businesswire.comSavara Mudigi Moved after Leading National Anthem Before Kenya vs Gabon MatchMarch 25 at 9:17 AM | msn.comEmerald Advisers LLC Acquires Shares of 2,332,680 Savara Inc (NASDAQ:SVRA)Emerald Advisers LLC bought a new position in Savara Inc (NASDAQ:SVRA - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 2,332,680 shares of the company's stock, valued at approximately $7,161,000. Emerald Advisers LLC owned about 1.36% oMarch 24, 2025 | marketbeat.comVictory Capital Management Inc. Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA)Victory Capital Management Inc. decreased its position in Savara Inc (NASDAQ:SVRA - Free Report) by 92.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,246 shares of the company's stock after selling 128March 24, 2025 | marketbeat.com2,654,944 Shares in Savara Inc (NASDAQ:SVRA) Acquired by Rosalind Advisors Inc.Rosalind Advisors Inc. bought a new position in shares of Savara Inc (NASDAQ:SVRA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,654,944 shares of the company's stock, vMarch 23, 2025 | marketbeat.comSavara Inc (NASDAQ:SVRA) Given Average Rating of "Moderate Buy" by BrokeragesMarch 22, 2025 | americanbankingnews.comSavara Inc (NASDAQ:SVRA) Holdings Raised by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 21.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 837,467 shares of the company'sMarch 18, 2025 | marketbeat.comSavara Inc (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by BrokeragesSavara Inc (NASDAQ:SVRA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating tMarch 17, 2025 | marketbeat.comSavara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung DiseaseMarch 11, 2025 | msn.comSavara Inc. to Present at Leerink Global Healthcare ConferenceMarch 10, 2025 | msn.comOppenheimer & Co. Inc. Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA)Oppenheimer & Co. Inc. lessened its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 86.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,600 shares of the company's stock after selling 100,004 sharesMarch 10, 2025 | marketbeat.comSavara Launches New Dried Blood Spot Test For APAP DiagnosisMarch 9, 2025 | nasdaq.comSauti Soul’s Savara Narrates Hilarious Experience after Getting Arrested in Tanzania: "Tulikamatwa"March 4, 2025 | msn.comSavara Announces Participation in the Leerink Global Healthcare ConferenceMarch 3, 2025 | finance.yahoo.comSavara (SVRA) Expected to Announce Earnings on ThursdaySavara (NASDAQ:SVRA) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comSavara Inc (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by BrokeragesSavara Inc (NASDAQ:SVRA - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation toFebruary 20, 2025 | marketbeat.comSavara Announces New Employment Inducement GrantFebruary 14, 2025 | businesswire.comPositive Signs As Multiple Insiders Buy Savara StockFebruary 8, 2025 | finance.yahoo.comSavara’s Molgramostim: Strong Buy Rating Backed by Clinical and Real-World Evidence for aPAP TreatmentJanuary 30, 2025 | markets.businessinsider.comSVRA stock touches 52-week low at $2.6 amid market challengesJanuary 30, 2025 | msn.comMolgramostim shows promise in rare lung disease treatmentJanuary 30, 2025 | msn.comSavara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open ResearchJanuary 30, 2025 | businesswire.comSavara Inc (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from AnalystsSavara Inc (NASDAQ:SVRA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to tJanuary 26, 2025 | marketbeat.comSavara sets executive bonus targets for 2025January 24, 2025 | msn.comSavara (NASDAQ:SVRA) Stock Price Down 5.3% - Here's What HappenedSavara (NASDAQ:SVRA) Shares Down 5.3% - What's Next?January 16, 2025 | marketbeat.comSavara (NASDAQ:SVRA) Shares Up 8.1% - Should You Buy?Savara (NASDAQ:SVRA) Stock Price Up 8.1% - Should You Buy?January 15, 2025 | marketbeat.comSavara Inc (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Savara Inc (NASDAQ:SVRA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendJanuary 1, 2025 | marketbeat.comGeode Capital Management LLC Raises Stock Holdings in Savara Inc (NASDAQ:SVRA)Geode Capital Management LLC raised its position in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 10.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,726,850 shares of the company's stock after buying an additionJanuary 1, 2025 | marketbeat.comSavara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the companyDecember 29, 2024 | uk.finance.yahoo.comSavara Inc. Grants Inducement Awards to New EmployeesDecember 29, 2024 | msn.comSavara Begins FDA Submission for Rare Lung Disease TreatmentDecember 27, 2024 | msn.comSavara Inc. to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 26, 2024 | msn.comState Street Corp Purchases 560,242 Shares of Savara Inc (NASDAQ:SVRA)State Street Corp boosted its position in Savara Inc (NASDAQ:SVRA - Free Report) by 15.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,138,276 shares of the company's stock after acquiring an additional 560,242December 25, 2024 | marketbeat.comSavara’s Strategic Pipeline Advancements and Promising Market Potential for Molbreevi: Analyst Issues Buy RatingDecember 21, 2024 | markets.businessinsider.comWells Fargo Initiates Coverage of Savara (SVRA) with Overweight RecommendationDecember 21, 2024 | msn.comSavara: Rolling BLA Submission Of MOLBREEVI Generates Catalysts To TrackDecember 20, 2024 | seekingalpha.comSavara initiated with an Overweight at Wells FargoDecember 20, 2024 | markets.businessinsider.comSavara Positioned for Success: Buy Rating Boosted by Strong BLA Progress and Market Potential for MolbreeviDecember 20, 2024 | markets.businessinsider.comSavara (NASDAQ:SVRA) Now Covered by Analysts at Wells Fargo & CompanyWells Fargo & Company started coverage on Savara in a report on Friday. They issued an "overweight" rating and a $8.00 price target for the company.December 20, 2024 | marketbeat.comSavara (NASDAQ:SVRA) Shares Up 5.6% - Time to Buy?Savara (NASDAQ:SVRA) Trading 5.6% Higher - What's Next?December 19, 2024 | marketbeat.comJMP Securities Reiterates "Market Outperform" Rating for Savara (NASDAQ:SVRA)JMP Securities reissued a "market outperform" rating and set a $9.00 price target on shares of Savara in a research note on Thursday.December 19, 2024 | marketbeat.comSavara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)December 18, 2024 | businesswire.comSavara Announces Participation in the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | businesswire.comSavara Inc (NASDAQ:SVRA) CEO Matthew Pauls Sells 54,702 SharesSavara Inc (NASDAQ:SVRA - Get Free Report) CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares of the company's stock, valued at approximately $5,085,414.49. The trade was a 3.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.December 16, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 642,259 Shares of Savara Inc (NASDAQ:SVRA)Charles Schwab Investment Management Inc. increased its position in Savara Inc (NASDAQ:SVRA - Free Report) by 238.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 911,617 shares of the company's stock aftDecember 15, 2024 | marketbeat.com Remove Ads Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address SVRA Media Mentions By Week SVRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SVRA News Sentiment▼0.320.78▲Average Medical News Sentiment SVRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SVRA Articles This Week▼133▲SVRA Articles Average Week Remove Ads Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TVTX News JANX News IRON News AGIO News SUPN News VERA News DVAX News GLPG News KNSA News SDGR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SVRA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
